AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6662004 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 0
Study 6662004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30714260 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled facemask ventilation at an inspiratory pressure of 13 cm H2O
Number of subjects: 151
Study 30714260 — intervention group
Group type: COMPARATOR
Intervention: Manual facemask ventilation at an inspiratory pressure of 13 cm H2O
Number of subjects: 151
Study 31158931 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric oxygen (NBO2) therapy
Number of subjects: 40
Study 31158931 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) therapy
Number of subjects: 40
Study 31158931 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 40
Study 27164985 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg for 3 days prior to surgery (including the day of surgery)
Number of subjects: 20
Study 27164985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24360571 — intervention group
Group type: COMPARATOR
Intervention: peginterferon α‐2a + RBV 800 mg/day (A; n=42)
Number of subjects: 97
Study 24360571 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon α‐2a + RBV 1600 mg/day + epoetin β 400 IU/kg/week SC (B; n=55)
Number of subjects: 97
Study 24360571 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon α‐2a + RBV 800 mg/day for a further 20 weeks (B1; n=42)
Number of subjects: 97
Study 24360571 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon α‐2a + RBV 1600 mg/day + epoetin β (B2; n=13)
Number of subjects: 97
Study 22586132 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate or heavy paternal alcohol consumption (at least weekly, ≥ 4 units per occasion)
Number of subjects: 0
Study 22586132 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition into stepfamilies
Number of subjects: 0
Study 22586132 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable single-parent families or transition into single-parent families
Number of subjects: 0
Study 20461765 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 500 mg/m(2) IV weekly for 6 weeks with radiation to 50.4 Gy
Number of subjects: 21
Study 20461765 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 175 mg/m(2) on days 1, 5, 29, and 33, cisplatin 20 mg/m(2) on days 1‐5 and 29‐32, 5‐FU 600 mg/m(2) on days 1‐5 and 29‐32, followed by radiation with continuous infusion 5‐FU 225 mg/m(2) for 6 weeks
Number of subjects: 21
Study 20461765 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B (gemcitabine, cisplatin, 5-FU)
Number of subjects: 21
Study 18789118 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD) patients
Number of subjects: 58
Study 18789118 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ambulatory peritoneal dialysis (CAPD) patients
Number of subjects: 58
Study 18789118 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 58
Study 18789118 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with shoulder pain
Number of subjects: 58
Study 16133138 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C with atypical antipsychotics
Number of subjects: 40
Study 16133138 — intervention group
Group type: COMPARATOR
Intervention: Placebo with atypical antipsychotics
Number of subjects: 40
Study 12924045 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (50 to 60 Gy of radiotherapy plus concurrent chemotherapy with 5-fluorouracil (5-FU) plus cisplatin)
Number of subjects: 0
Study 12924045 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0
Study 12924045 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative radiotherapy and chemotherapy with 5-FU plus cisplatin
Number of subjects: 0
Study 10229251 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of a light breakfast and 2 phosphate enemas
Number of subjects: 429
Study 10229251 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional preparatory measures (dietary restrictions and phospho-soda oral saline laxative)
Number of subjects: 429
Study 8735074 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral acoustic stimulation (CAS) with contralateral broadband noise (BBN)
Number of subjects: 64
Study 8735074 — intervention group
Group type: COMPARATOR
Intervention: No contralateral acoustic stimulation (CAS)
Number of subjects: 64
Study 8735074 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral acoustic stimulation (CAS)
Number of subjects: 64
Study 1867076 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.2 mg/kg body weight infused over 5 min)
Number of subjects: 9
Study 1867076 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 9
Study 7048913 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 10
Study 7048913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30787276 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 20
Study 27619750 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (420 mg, monthly subcutaneous)
Number of subjects: 905
Study 27619750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 905
Study 27619750 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 905
Study 27053444 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard primary PCI with immediate stent implantation
Number of subjects: 1215
Study 27053444 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred stent implantation
Number of subjects: 1215
Study 25251888 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills training (CST)
Number of subjects: 326
Study 21913027 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-bicarbonated mineral water (BW) with a standard meal
Number of subjects: 0
Study 21913027 — intervention group
Group type: COMPARATOR
Intervention: Sodium-bicarbonated mineral water (BW) without a meal
Number of subjects: 0
Study 21913027 — intervention group
Group type: COMPARATOR
Intervention: Low mineral content water (CW) with a standard meal
Number of subjects: 0
Study 21913027 — intervention group
Group type: COMPARATOR
Intervention: Low mineral content water (CW) without a meal
Number of subjects: 0
Study 19507295 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 133
Study 19507295 — intervention group
Group type: EXPERIMENTAL
Intervention: Montessori-based activities
Number of subjects: 133
Study 19507295 — intervention group
Group type: COMPARATOR
Intervention: Presence (control group)
Number of subjects: 133
Study 17475133 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered toes with a sterile glove
Number of subjects: 40
Study 17475133 — intervention group
Group type: COMPARATOR
Intervention: Uncovered toes
Number of subjects: 40
Study 15341545 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 279
Study 15341545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 17163298 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 5mg
Number of subjects: 120
Study 17163298 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 2.5mg
Number of subjects: 120
Study 17163298 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study 11110009 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg, 100 mg, or 200 mg)
Number of subjects: 322
Study 11110009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 9162222 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF plus IFN-alpha
Number of subjects: 20
Study 9162222 — intervention group
Group type: COMPARATOR
Intervention: IFN-alpha alone
Number of subjects: 20
Study 1363700 — intervention group
Group type: EXPERIMENTAL
Intervention: poly‐saccharide sulphate (PSS)
Number of subjects: 30
Study 1363700 — intervention group
Group type: COMPARATOR
Intervention: DX40
Number of subjects: 30
Study 6373033 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticholera vaccine
Number of subjects: 36640
Study 6373033 — intervention group
Group type: EXPERIMENTAL
Intervention: Injected anticholera vaccine
Number of subjects: 36640
Study 6373033 — intervention group
Group type: COMPARATOR
Intervention: Non-inoculated group
Number of subjects: 36640
Study 28952858 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise protocol
Number of subjects: 4
Study 28952858 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 4
Study 28952858 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 4
Study 29316845 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-210
Number of subjects: 0
Study 29316845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28262195 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional heart failure treatment combined with an individualized nutritional intervention
Number of subjects: 120
Study 28262195 — intervention group
Group type: COMPARATOR
Intervention: Conventional heart failure treatment
Number of subjects: 120
Study 24484452 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with prednisolone
Number of subjects: 102
Study 24484452 — intervention group
Group type: COMPARATOR
Intervention: Control group (RTR without pulmonary symptoms)
Number of subjects: 102
Study 22065156 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg daily
Number of subjects: 1000
Study 22065156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 20921038 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Manual programme (one-to-one structured educational intervention)
Number of subjects: 12
Study 20921038 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Manual programme
Number of subjects: 12
Study 17137836 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spine manipulation
Number of subjects: 24
Study 17137836 — intervention group
Group type: COMPARATOR
Intervention: Passive head movement
Number of subjects: 24
Study 15831419 — intervention group
Group type: EXPERIMENTAL
Intervention: Spherical harmonics (SH) method for approximating 3D shape and estimating volume of brain tumors
Number of subjects: 5
Study 15831419 — intervention group
Group type: EXPERIMENTAL
Intervention: Spherical harmonics (SH) method
Number of subjects: 5
Study 11888098 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid 0.5mg/kg/day
Number of subjects: 120
Study 11888098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 10028201 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to PAHs
Number of subjects: 235
Study 10028201 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to asbestos
Number of subjects: 235
Study 10028201 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with overt cancer
Number of subjects: 235
Study 10028201 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 235
Study 7626370 — intervention group
Group type: EXPERIMENTAL
Intervention: Zamic (ZA)
Number of subjects: 24
Study 7626370 — intervention group
Group type: COMPARATOR
Intervention: Arginine aspartate (AA)
Number of subjects: 24
Study 31830787 — intervention group
Group type: EXPERIMENTAL
Intervention: Coherent superposition of Fermi resonant eigenstates
Number of subjects: 0
Study 31830787 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy gaps (Δν̃) of eigenstates
Number of subjects: 0
Study 31830787 — intervention group
Group type: EXPERIMENTAL
Intervention: Dephasing rate
Number of subjects: 0
Study 31209667 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsatellite stable (MSS) patients
Number of subjects: 1650
Study 31209667 — intervention group
Group type: EXPERIMENTAL
Intervention: MSI patients
Number of subjects: 1650
Study 31209667 — intervention group
Group type: EXPERIMENTAL
Intervention: MSS population with RAS or BRAF mutations
Number of subjects: 1650
Study 31209667 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence in peritoneum or more than two recurrence sites
Number of subjects: 1650
Study 28028768 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine HCl (1500 mg) after rabeprazole pretreatment
Number of subjects: 0
Study 28028768 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole (20 mg twice daily)
Number of subjects: 0
Study 26589718 — intervention group
Group type: EXPERIMENTAL
Intervention: Early stoma closure (8-10 days after resection, before starting adjuvant therapy)
Number of subjects: 257
Study 26589718 — intervention group
Group type: COMPARATOR
Intervention: Late stoma closure (26 weeks after resection and completion of adjuvant therapy)
Number of subjects: 257
Study 26589718 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 257
Study 26589718 — intervention group
Group type: EXPERIMENTAL
Intervention: Stoma-related complications
Number of subjects: 257
Study 26589718 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual completeness of chemotherapy rate
Number of subjects: 257
Study 26589718 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of patients stopping adjuvant therapy or undergoing dose modifications or delay
Number of subjects: 257
Study 26589718 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncological outcomes
Number of subjects: 257
Study 26589718 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative days of hospitalisation
Number of subjects: 257
Study 26589718 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of readmissions
Number of subjects: 257
Study 26589718 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of symptomatic anastomotic leaks after stoma closure
Number of subjects: 257
Study 26589718 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 257
Study 26589718 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative complications
Number of subjects: 257
Study 26589718 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicity of adjuvant chemotherapy
Number of subjects: 257
Study 22816533 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg per day
Number of subjects: 50
Study 22816533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 21355155 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with Amitriptyline
Number of subjects: 86
Study 21355155 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin combined with Amitriptyline
Number of subjects: 86
Study 19389718 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral temporal lobe resection (either temporal lobectomy, selective amygdalohippocampectomy or lesionectomy)
Number of subjects: 17
Study 19389718 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative functional activation in the right mesial temporal lobe
Number of subjects: 17
Study 19389718 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative functional activation in the left mesial temporal lobe
Number of subjects: 17
Study 19389718 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative memory performance
Number of subjects: 17
Study 16760874 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioguided surgery (scinti-probe technique)
Number of subjects: 30
Study 16760874 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography-guided hookwire localization
Number of subjects: 30
Study 15130206 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential learning intervention (integrated, end-of-life clinical pathway: PEACE Tool)
Number of subjects: 54
Study 15130206 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 54
Study 11420161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning
Number of subjects: 43
Study 11420161 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 9413374 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 67
Study 9413374 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 67
Study 8103013 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide at 3 x 100 micrograms/day subcutaneously
Number of subjects: 0
Study 8103013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3613879 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 154
Study 3613879 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 154
Study 29413370 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised center-based exercise training (ET) for 24 weeks
Number of subjects: 278
Study 29413370 — intervention group
Group type: COMPARATOR
Intervention: Supported home exercise program (control)
Number of subjects: 278
Study 29413370 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who exercised to guidelines (intervention)
Number of subjects: 278
Study 29413370 — intervention group
Group type: COMPARATOR
Intervention: Participants who exercised to guidelines (control)
Number of subjects: 278
Study 27216479 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium triformate mouthrinse (ATF)
Number of subjects: 40
Study 27216479 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 40
Study 24112601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle bracing
Number of subjects: 15
Study 24112601 — intervention group
Group type: COMPARATOR
Intervention: No brace
Number of subjects: 15
Study 23080059 — intervention group
Group type: EXPERIMENTAL
Intervention: lotrafilcon B, CIBA Vision
Number of subjects: 446
Study 23080059 — intervention group
Group type: EXPERIMENTAL
Intervention: omafilcon A, CooperVision
Number of subjects: 446
Study 23080059 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrogen peroxide care system (Clear Care, CIBAVision)
Number of subjects: 446
Study 23080059 — intervention group
Group type: COMPARATOR
Intervention: none
Number of subjects: 446
Study 20467406 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) injections (average molecular weight 1.5 million Da), 3 injections at weeks 1, 2, and 3
Number of subjects: 48
Study 20467406 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline), 3 injections at weeks 1, 2, and 3
Number of subjects: 48
Study 18384679 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg daily
Number of subjects: 0
Study 18384679 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 30 mg daily
Number of subjects: 0
Study 18384679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16005691 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol test formulation from Laboratórios Biosintética Ltda
Number of subjects: 0
Study 16005691 — intervention group
Group type: COMPARATOR
Intervention: Coreg from Roche Químicos e Farmacêuticos S.A standard reference formulation
Number of subjects: 0
Study 12698397 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH-based strategy with AT III
Number of subjects: 100
Study 12698397 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH-based strategy with r-hirudin
Number of subjects: 100
Study 12698397 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH-based strategy with tirofiban
Number of subjects: 100
Study 12698397 — intervention group
Group type: COMPARATOR
Intervention: ACT management
Number of subjects: 100
Study 12698397 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH-based strategy
Number of subjects: 100
Study 12698397 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH-based strategy with AT III, r-hirudin, or tirofiban
Number of subjects: 100
Study 10488513 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical discectomy
Number of subjects: 40
Study 10488513 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemonucleolysis
Number of subjects: 40
Study 10488513 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdiscectomy
Number of subjects: 40
Study 10488513 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard discectomy
Number of subjects: 40
Study 10488513 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdiscectomy and standard discectomy
Number of subjects: 40
Study 10488513 — intervention group
Group type: EXPERIMENTAL
Intervention: Interposition membrane after discectomy
Number of subjects: 40
Study 10488513 — intervention group
Group type: COMPARATOR
Intervention: Instrumented fusion
Number of subjects: 40
Study 10488513 — intervention group
Group type: COMPARATOR
Intervention: Noninstrumented fusion
Number of subjects: 40
Study 10488513 — intervention group
Group type: COMPARATOR
Intervention: Surgical decompression or fusion for degenerative lumbar spondylosis
Number of subjects: 40
Study 8724711 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) using expanded polytetrafluoroethylene (ePTFE) membranes
Number of subjects: 28
Study 8724711 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine home care with daily chlorhexidine rinse and systemic tetracycline
Number of subjects: 28
Study 8724711 — intervention group
Group type: EXPERIMENTAL
Intervention: Sites with minimal or no plaque (plaque index [PI] <= 1)
Number of subjects: 28
Study 8724711 — intervention group
Group type: EXPERIMENTAL
Intervention: Sites with no Actinobacillus actinomycetemcomitans
Number of subjects: 28
Study 8724711 — intervention group
Group type: EXPERIMENTAL
Intervention: Sites with Porphyromonas gingivalis
Number of subjects: 28
Study 8724711 — intervention group
Group type: EXPERIMENTAL
Intervention: Pi-infected sites
Number of subjects: 28
Study 8724711 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with membrane barriers
Number of subjects: 28
Study 1720828 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 42‐5892 (10‐min infusion, doses ranging from 0.001 to 1 mg/kg)
Number of subjects: 38
Study 1720828 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 42‐5892 (100, 600, or 1,200 mg p.o.)
Number of subjects: 38
Study 1720828 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 42‐5892 (1,200 mg p.o.)
Number of subjects: 38
Study 1720828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 1720828 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 42‐5892
Number of subjects: 38